Archives: “Archives”

Precision Targeting of Lupus-Associated IGHV4-34+ Pathogenic B Cells Using Chimeric Antigen Receptor T Cells

Developing CART4-34, a novel CAR T cell therapy that selectively eliminates IGHV4-34+ pathogenic B cells in lupus while sparing healthy B cells and avoiding broad immunosuppression.

Center of Excellence for Cell Therapy in Autoimmunity (CECTA)

Advancing engineered CAR and CAAR T cell therapies across multiple autoimmune diseases through clinical trials, preclinical development, and industry partnerships.

Colton Center for RNA Exploration in Autoimmune Therapeutics (CREATE)

Developing next-generation mRNA-LNP therapeutics that selectively modulate or deplete pathogenic immune cells to treat type 1 diabetes, lupus, multiple sclerosis, and other severe autoimmune conditions.

Profiling Urine Methylation in Lupus Nephritis

Identifying urine DNA methylation signatures as a non-invasive biomarker for lupus nephritis class and disease progression.

Transcription factor Etv3 controls the tolerogenic function of dendritic cells

You might also be interested in… Soluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis Rheumatology Chu, D; Schwartz, N; Ampudia, J; Guthridge, J; James, […]

Soluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis

Substantiation of trophoblast transport of maternal anti-SSA/Ro autoantibodies in fetuses with rapidly progressive cardiac injury: implications for neonatal Fc receptor blockade

T-bet+CD11c+ age-associated B cells resist BLyS- and CD20-targeted ablation in murine lupus models

Longitudinal gut microbiome analyses and blooms of pathogenic strains during lupus disease flares

Organ injury in systemic autoimmunity is mediated by stem-like CD8+ T cells arising from tissue-draining lymph nodes